These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31446969)

  • 61. [Serum metabolomics analysis on benign prostate hyperplasia in mice based on liquid chromatography-mass spectrometry].
    Geng Y; Sun F; Ma Y; Deng L; Lü J; Li T; Wang C
    Se Pu; 2014 Dec; 32(12):1301-5. PubMed ID: 25902635
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Metabolic Profiling in Formalin-Fixed and Paraffin-Embedded Prostate Cancer Tissues.
    Cacciatore S; Zadra G; Bango C; Penney KL; Tyekucheva S; Yanes O; Loda M
    Mol Cancer Res; 2017 Apr; 15(4):439-447. PubMed ID: 28074002
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer.
    Kumar V; Dwivedi DK; Jagannathan NR
    NMR Biomed; 2014 Jan; 27(1):80-9. PubMed ID: 23828638
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer.
    Jerónimo C; Usadel H; Henrique R; Silva C; Oliveira J; Lopes C; Sidransky D
    Urology; 2002 Dec; 60(6):1131-5. PubMed ID: 12475696
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.
    Irani J; Millet C; Levillain P; Doré B; Begon F; Aubert J
    Eur Urol; 1996; 29(4):407-12. PubMed ID: 8791046
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Strategy for NMR metabolomic analysis of urine in mouse models of obesity--from sample collection to interpretation of acquired data.
    Pelantová H; Bugáňová M; Anýž J; Železná B; Maletínská L; Novák D; Haluzík M; Kuzma M
    J Pharm Biomed Anal; 2015 Nov; 115():225-35. PubMed ID: 26263053
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of metabolites from 2D (1)H-(13)C HSQC NMR using peak correlation plots.
    Öman T; Tessem MB; Bathen TF; Bertilsson H; Angelsen A; Hedenström M; Andreassen T
    BMC Bioinformatics; 2014 Dec; 15(1):413. PubMed ID: 25511422
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Metabolomics studies in brain tissue: A review.
    Gonzalez-Riano C; Garcia A; Barbas C
    J Pharm Biomed Anal; 2016 Oct; 130():141-168. PubMed ID: 27451335
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Endocrine patterns in patients with benign and malignant prostatic diseases.
    Schatzl G; Reiter WJ; Thürridl T; Waldmüller J; Roden M; Söregi S; Madersbacher S
    Prostate; 2000 Aug; 44(3):219-24. PubMed ID: 10906738
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sample normalization methods in quantitative metabolomics.
    Wu Y; Li L
    J Chromatogr A; 2016 Jan; 1430():80-95. PubMed ID: 26763302
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The urine metabolome differs between lean and overweight Labrador Retriever dogs during a feed-challenge.
    Söder J; Hagman R; Dicksved J; Lindåse S; Malmlöf K; Agback P; Moazzami A; Höglund K; Wernersson S
    PLoS One; 2017; 12(6):e0180086. PubMed ID: 28662207
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
    Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
    Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Urine metabolomics.
    Zhang A; Sun H; Wu X; Wang X
    Clin Chim Acta; 2012 Dec; 414():65-9. PubMed ID: 22971357
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An LC-MS-based metabolomics approach for exploring urinary metabolome modifications after cocoa consumption.
    Llorach R; Urpi-Sarda M; Jauregui O; Monagas M; Andres-Lacueva C
    J Proteome Res; 2009 Nov; 8(11):5060-8. PubMed ID: 19754154
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Use of Charged Nanoparticles in NMR-Based Metabolomics for Spectral Simplification and Improved Metabolite Identification.
    Zhang B; Xie M; Bruschweiler-Li L; Bingol K; Brüschweiler R
    Anal Chem; 2015 Jul; 87(14):7211-7. PubMed ID: 26087125
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: a preliminary report.
    Narayan P; Jajodia P; Kurhanewicz J; Thomas A; MacDonald J; Hubesch B; Hedgcock M; Anderson CM; James TL; Tanagho EA
    J Urol; 1991 Jul; 146(1):66-74. PubMed ID: 1711587
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: a Pilot Study.
    Dereziński P; Klupczynska A; Sawicki W; Pałka JA; Kokot ZJ
    Int J Med Sci; 2017; 14(1):1-12. PubMed ID: 28138303
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Study on plasmatic metabolomics of Uygur patients with essential hypertension based on nuclear magnetic resonance technique.
    Zhong L; Zhang JP; Nuermaimaiti AG; Yunusi KX
    Eur Rev Med Pharmacol Sci; 2014; 18(23):3673-80. PubMed ID: 25535139
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.
    Tokmadžić VS; Tomaš MI; Sotošek S; Laškarin G; Dominović M; Tulić V; Dorđević G; Sustić A; Mrakovčić-Šutić I
    Scand J Immunol; 2011 Oct; 74(4):368-76. PubMed ID: 21535078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.